Evidence map›Paper›PMID 34079616›Full record

ArticleNano research2020

PLGA nanodepots co-encapsulating prostratin and anti-CD25 enhance primary natural killer cell antiviral and antitumor function.

Elizabeth E Sweeney, Preethi B Balakrishnan, Allison B Powell, Allan Bowen, Indra Sarabia, Rachel A Burga, R Brad Jones, Alberto Bosque, C Russell Y Cruz, Rohan Fernandes

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nano research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. NK cell-based tumor immunotherapy.Bioactive materials · 2024
    Review
  4. Article
  5. Article
  6. Review
  7. Nanoparticles in Clinical Translation for Cancer Therapy.International journal of molecular sciences · 2022
    Review
  8. Review
  9. Article
  10. Nanosystems Applied to HIV Infection: Prevention and Treatments.International journal of molecular sciences · 2020
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Elizabeth E SweeneyThe George Washington Cancer Center, The George Washington University, Washington, DC 20052, USA.
Preethi B BalakrishnanThe George Washington Cancer Center, The George Washington University, Washington, DC 20052, USA.
Allison B PowellCenter for Cancer and Immunology Research, Children's National Health System, Washington, DC 20010, USA.
Allan BowenThe George Washington Cancer Center, The George Washington University, Washington, DC 20052, USA.
Indra SarabiaDepartment of Microbiology, Immunology, and Tropical Medicine, The George Washington University, Washington, DC 20052, USA.
Rachel A BurgaThe George Washington Cancer Center, The George Washington University, Washington, DC 20052, USA.
R Brad JonesInfectious Disease Division, Weill Cornell Medical College, New York, NY 10065, USA.
Alberto BosqueDepartment of Microbiology, Immunology, and Tropical Medicine, The George Washington University, Washington, DC 20052, USA.
C Russell Y CruzThe George Washington Cancer Center, The George Washington University, Washington, DC 20052, USA.
Rohan FernandesThe George Washington Cancer Center, The George Washington University, Washington, DC 20052, USA.
George Washington University · USChildren's National · USCornell University · US

Funding

Biomaterials-Enhanced NK Cells for Improved Elimination of the HIV ReservoirR21AI136102 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI CRUZ, CONRAD RUSSELL YOUNG, FERNANDES, ROHAN · 2018 to 2019
$435k
NIAID NIH HHS R21 AI136102
6 · The paper itself

Abstract

Natural killer (NK) cells are attractive effector cells of the innate immune system against human immunodeficiency virus (HIV) and cancer. However, NK cell therapies are limited by the fact that target cells evade NK cells, for example, in latent reservoirs (in HIV) or through upregulation of inhibitory signals (in cancer). To address this limitation, we describe a biodegradable nanoparticle-based "priming" approach to enhance the cytotoxic efficacy of peripheral blood mononuclear cell-derived NK cells. We present poly(lactic-co-glycolic acid) (PLGA) nanodepots (NDs) that co-encapsulate prostratin, a latency-reversing agent, and anti-CD25 (aCD25), a cell surface binding antibody, to enhance primary NK cell function against HIV and cancer. We utilize a nanoemulsion synthesis scheme to encapsulate both prostratin and aCD25 within the PLGA NDs (termed Pro-aCD25-NDs). Physicochemical characterization studies of the NDs demonstrated that our synthesis scheme resulted in stable and monodisperse Pro-aCD25-NDs. The NDs successfully released both active prostratin and anti-CD25, and with controllable release kinetics. When Pro-aCD25-NDs were administered in an

Indexed as

antibodycancerhuman immunodeficiency virus (HIV)latency-reversing agentnatural killer (NK) cellspoly(lactic-co-glycolic acid) (PLGA) nanodepots

Identifiers

PMID34079616
PMCPMC8168447
OpenAlexW3008428957

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.